Now a team of researchers from the Network for Neutrinos, Nuclear Astrophysics, and Symmetries (N3AS), including several from UC San Diego, have shown, through theoretical calculations, how collapsing massive stars can act as a “neutrino collider.” Neutrinos steal thermal energy from these stars, forcing them to contract and causing their electrons to move near light speed. This drives the stars to instability and collapse

Eventually the collapsing star’s density becomes so high that the neutrinos are trapped and collide with each other. With purely standard model interactions, the neutrinos will be mostly electron flavor, the matter will be relatively “cold,” and the collapse will likely leave a neutron star remnant. However, secret interactions that change neutrino flavor radically alter this scenario, producing neutrinos of all flavors and leading to a mostly neutron “hot” core that may lead to a black hole remnant.

Fermi National Accelerator Lab’s upcoming Deep Underground Neutrino Experiment (DUNE) might be able to test these ideas, as might future observations of the neutrinos or gravitational waves from collapsing stars.

The study, published June 18, 2025 in Physical Review Letters, was led by UC San Diego researchers Anna M. Suliga, Julien Froustey, Lukáš Gráf, Kyle Kehrer and George Fuller, as well as collaborators from other institutions. Their research was funded, in part, by the National Science Foundation (PHY-2209578 and PHY-2020275), the Department of Energy (DE-AC02-07CHI11359), and the Heising-Simons Foundation (2017-228).

Dementias such as Alzheimer’s disease are estimated to affect more than 57.4 million people worldwide, a number that is expected to almost triple to 152.8 million cases by 2050. The impacts on the individuals, families and caregivers and society at large are immense.

While there are some indications that the prevalence of dementia is decreasing in Europe and North America, suggesting that it may be possible to reduce the risk of the disease at a population level, elsewhere the picture is less promising.

Air pollution has recently been identified as a risk factor for dementia, with several studies pointing the finger at a number of pollutants. However, the strength of evidence and ability to determine a causal effect has been varied.

In a paper published on July 24 in The Lancet Planetary Health, a team led by researchers at the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, carried out a systematic review and meta-analysis of existing scientific literature to examine this link further. This approach allowed them to bring together studies that on their own may not provide sufficient evidence, and which sometimes disagree with each other, to provide more robust overarching conclusions.

In total, the researchers included 51 studies, including data from more than 29 million participants, mostly from high-income countries. Of these, 34 papers were included in the meta-analysis: 15 originated in North America, 10 in Europe, seven in Asia, and two in Australia.

The researchers found a positive and statistically-significant association between three types of air pollutant and dementia. These were:

• Particulate matter with a diameter of 2.5 microns or less (PM_2.5), a pollutant made up of tiny particles small enough that they can be inhaled deep into the lungs. These particles come from several sources, including vehicle emissions, power plants, industrial processes, wood burning stoves and fireplaces, and construction dust. They also form in the atmosphere because of complex chemical reactions involving other pollutants such as sulphur dioxide and nitrogen oxides. The particles can stay in the air for a long time and travel a long way from where they were produced.

• Nitrogen dioxide (NO₂), one of the key pollutants that arise from burning fossil fuels. It is found in vehicle exhaust, especially diesel exhaust, and industrial emissions, as well as those from gas stoves and heaters. Exposure to high concentrations of nitrogen dioxide can irritate the respiratory system, worsening and inducing conditions like asthma and reducing lung function.
• Soot, from sources such as vehicle exhaust emissions and burning wood. It can trap heat and affect the climate. When inhaled, it can penetrate deep into the lungs, aggravating respiratory diseases and increasing the risk of heart problems.

According to the researchers, for every 10 micrograms per cubic meter (μg/m³) of PM_2.5, an individual’s relative risk of dementia would increase by 17%. The average roadside measurement for PM_2.5 in Central London in 2023 was 10 μg/m³.

For every 10 μg/m³ of NO₂, the relative risk increased by 3%. The average roadside measurement for NO₂ in Central London in 2023 was 33 µg/m³.

For each 1 μg/m³ of soot as found in PM_2.5, the relative risk increased by 13%. Across the UK, annual mean soot concentrations measured at select roadside locations in 2023 were 0.93 μg/m³ in London, 1.51 μg/m³ in Birmingham and 0.65 μg/m³ Glasgow.

Senior author Dr Haneen Khreis from the MRC Epidemiology Unit said: “Epidemiological evidence plays a crucial role in allowing us to determine whether or not air pollution increases the risk of dementia and by how much. Our work provides further evidence to support the observation that long-term exposure to outdoor air pollution is a risk factor for the onset of dementia in previously healthy adults.

“Tackling air pollution can deliver long-term health, social, climate, and economic benefits. It can reduce the immense burden on patients, families, and caregivers, while easing pressure on overstretched healthcare systems.”

Several mechanisms have been proposed to explain how air pollution may cause dementia, primarily involving inflammation in the brain and oxidative stress (a chemical process in the body that can cause damage to cells, proteins, and DNA). Both oxidative stress and inflammation play a well-established role in the onset and progression of dementia. Air pollution is thought to trigger these processes through direct entry to the brain or via the same mechanisms underlying lung and cardiovascular diseases. Air pollution can also enter circulation from the lungs and travel to solid organs, initiating local and wide-spread inflammation.

The researchers point out that the majority of people included in the published studies were white and living in high-income countries, even though marginalised groups tend to have a higher exposure to air pollution. Given that studies have suggested that reducing air pollution exposure appears to be more beneficial at reducing the risk of early death for marginalised groups, they call for future work to urgently ensure better and more adequate representation across ethnicities and low- and middle-income countries and communities.

Joint first author Clare Rogowski, also from the MRC Epidemiology Unit, said: “Efforts to reduce exposure to these key pollutants are likely to help reduce the burden of dementia on society. Stricter limits for several pollutants are likely to be necessary targeting major contributors such as the transport and industry sectors. Given the extent of air pollution, there is an urgent need for regional, national, and international policy interventions to combat air pollution equitably.”

Further analysis revealed that while exposure to these pollutants increased the risk of Alzheimer’s disease, the effect seemed stronger for vascular dementia, a type of dementia caused by reduced blood flow to the brain. Around 180,000 people in the UK are thought to be affected by this type of dementia. However, as there were only a small number of studies that examined this difference, the researchers did not class it as statistically significant.

Joint first author Dr Christiaan Bredell from the University of Cambridge and North West Anglia NHS Foundation Trust said: “These findings underscore the need for an interdisciplinary approach to dementia prevention. Preventing dementia is not just the responsibility of healthcare: this study strengthens the case that urban planning, transport policy, and environmental regulation all have a significant role to play.”

The research was funded by the European Research Council under the Horizon 2020 research and innovation program and from the European Union’s Horizon Europe Framework Programme.

A major new study led by the University of Sydney suggests that walking 7000 steps a day offers similar health benefits across several outcomes as walking 10,000.

Led by Professor Melody Ding from the School of Public Health, the study was published in The Lancet Public Healthand analysed data from 57 studies from 2014 to 2025 that were conducted in more than ten countries including Australia, USA, UK and Japan.

The largest and most comprehensive review to date, the researchers examined the impact that different daily step counts have on the chance of dying from cardiovascular disease and cancer, and developing diseases such as cancer, type 2 diabetes, dementia and depression. Professor Melody Ding says the findings offer a more achievable benchmark for people who struggle to meet traditional exercise guidelines.

“Aiming for 7000 steps is a realistic goal based on our findings, which assessed health outcomes in a range of areas that hadn’t been looked at before,” said Professor Ding.

“However, for those who cannot yet achieve 7000 steps a day, even small increases in step counts, such as increasing from 2000 to 4000 steps a day, are associated with significant health gain.

“We know daily step count is linked to living longer, but we now also have evidence that walking at least 7000 steps a day can significantly improve eight major health outcomes — including reducing risk of cardiovascular disease, dementia and depressive symptoms.”

Health benefits at different step counts

The researchers looked at studies in which participants wore step counting devices, such as pedometers, accelerometers and fitness trackers, to track their daily step counts. Starting at 2000 steps, experts compared the health outcomes of people walking more steps a day at 1000 step increments to see whether there was any difference in the risk of early death or other major diseases.

When compared with 2000 steps a day, researchers found that:

• Walking 7000 steps a day reduced the risk of death by 47 percent, which was almost identical to the benefit seen at walking 10,000 steps per day.
• Dementia risk dropped by 38 percent from walking 7000 steps a day, with only a 7 percent extra reduction at 10,000 steps.
• Risk of type 2 diabetes fell by 22 percent from walking 10,000 steps a day and reduced to 27 percent at 12,000 steps.
• Significant health improvements were seen when people increased their average daily steps from 2000 to between 5000 and 7000 steps.

“For people who are already active, 10,000 steps a day is great,” said Dr Katherine Owen, co-author and chief analyst of the study from the School of Public Health. “But beyond 7000 steps, the extra benefits for most of the health outcomes we looked at were modest.”

The researchers are working with the Australian government to use the evidence from this study to inform future updates to physical activity guidelines.

“Our research helps to shift the focus from perfection to progress. Even small increases in daily movement can lead to meaningful health improvements,” said Professor Ding.

Experts are calling for future studies to explore how step goals should vary based on age, health status and region, and to include diverse populations and longer-term data to strengthen the evidence. Professor Ding says this kind of detail is rare and will be useful for health practitioners when tailoring advice for patients.

These events pose severe threats to marine ecosystems, often resulting in widespread coral bleaching and mass mortality events. They also carry serious economic consequences by disrupting fisheries and aquaculture. It’s widely understood that human-driven climate change is driving a rapid increase in the frequency and intensity of MHWs.

In 2023, regions across the globe, including the North Atlantic, Tropical Pacific, South Pacific, and North Pacific, experienced extreme MHWs. However, the causes underlying the onset, persistence, and intensification of widespread MHWs remain poorly understood.

To better understand the MHWs of 2023, Tianyun Dong and colleagues conducted a global analysis using combined satellite observations and ocean reanalysis data, including those from the ECCO2 (Estimating the Circulation and Climate of the Ocean-Phase II) high-resolution project.

According to the findings, MHWs of 2023 set new records for intensity, duration, and geographic extent, lasting four times the historical average and covering 96% of the global ocean surface. Regionally, the most intense warming occurred in the North Atlantic, Tropical Eastern Pacific, North Pacific, and Southwest Pacific, collectively accounting for 90% of the oceanic heating anomalies.

The researchers show that the North Atlantic MHW, which began as early as mid-2022, persisted for 525 days, while the Southwest Pacific event broke prior records with its vast spatial extent and prolonged duration. What’s more, in the Tropical Eastern Pacific, temperature anomalies peaked at 1.63 degrees Celsius during the onset of El Niño.

Using a mixed-layer heat budget analysis, the scientists discovered diverse regional drivers contributing to the formation and persistence of these events, including increased solar radiation due to reduced cloud cover, weakened winds, and ocean current anomalies. According to the researchers, the 2023 MHWs may mark a fundamental shift in ocean-atmosphere dynamics, potentially serving as an early warning of an approaching tipping point in Earth’s climate system.

Malaria remains a global health challenge, with 263 million cases and 597,000 deaths reported in 2023. Current vector control methods, such as long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS), have become less effective due to insecticide resistance and behavioral adaptations in mosquitoes to bite outdoors and during dusk or dawn, when people are not protected by these measures. This underscores the urgent need for innovative solutions to combat malaria.

Ivermectin for malaria: A novel strategy

Ivermectin, a drug traditionally used to treat neglected tropical diseases like onchocerciasis, which causes river blindness, and lymphatic filariasis, which causes elephantiasis, has been shown to reduce malaria transmission by killing the mosquitoes that feed on treated individuals. Given the rising resistance to conventional insecticides, ivermectin could offer an effective new approach totackle malaria transmission, especially in regions where traditional methods have become less effective.

The Unitaid-funded BOHEMIA project(Broad One Health Endectocide-based Malaria Intervention in Africa) conducted two Mass Drug Administration (MDA) trials in the high-burden malaria regions: Kwale County (Kenya) and Mopeia district (Mozambique). The trials assessed the safety and efficacy of a single monthly dose of ivermectin (400 mcg/kg) given for three consecutive months at the start of the rainy season in reducing malaria transmission. In Kenya, the intervention targeted children aged 5-15, while in Mozambique it focused on children under five.

Malaria reduction in Kenya

In Kwale County, Kenya, children who received ivermectin experienced a 26% reduction in malaria infection incidence compared to those who received albendazole, the control drug used in the study. The trial involved over 20,000 participants and more than 56,000 treatments, demonstrating that ivermectin significantly reduced malaria infection rates — particularly among children living further from cluster borders or in areas where drug distribution was more efficient. Moreover, the safety profile of ivermectin was favorable, with no severe drug-related adverse events and only mild, transient side effects already seen with ivermectin in campaigns against neglected tropical diseases.

“We are thrilled with these results,” says Carlos Chaccour, co-principal investigator of the BOHEMIA project and ISGlobal researcher at the time of the study. “Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures. With continued research, ivermectin MDA could become an effective tool for malaria control and even contribute to elimination efforts,” Chaccour, who is now a researcher at the Navarra Centre for International Development at the University of Navarra, adds.

“These results align with the World Health Organization’s (WHO) criteria for new vector control tools,” states Joseph Mwangangi, from the KEMRI-Wellcome Trust Research Programme. “The findings suggest that ivermectin MDA could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern,” adds Marta Maia, BOHEMIA’s lead entomologist from the University of Oxford.

Lessons from the Mozambique trial

In contrast, the implementation of the Mozambique trial in the rural district of Mopeia faced severe disruptions due to Cyclone Gombe (2022) and a subsequent cholera outbreak, which significantly disrupted operations. “One of the most important lessons we learned from the trial in Mopeia is that strong community engagement is essential,” states Francisco Saúte, director of the Manhiça Health Research Centre (CISM). “Building trust with local communities and fostering close collaboration with the Health Ministry, National Malaria Control Program, and local authorities was key to ensuring acceptance of the ivermectin MDA.”

Expanding the Impact Beyond Malaria

In addition to reducing malaria transmission, ivermectin MDA offers significant collateral benefits. The BOHEMIA team found an important reduction in the prevalence of skin infestations such as scabies and head lice in the ivermectin group in Mozambique, and the community reported a major reduction in bed bugs in Kenya. These effects are particularly valuable when ivermectin is integrated into existing delivery systems, maximizing its impact on public health.

Shaping the future of malaria prevention

The study is part of a larger global effort to assess ivermectin’s potential in malaria control. The findings have been reviewed by the WHO vector control advisory group, which concluded that the study had demonstrated impact and recommended further studies. Findings were also shared with national health authorities as they evaluate the potential inclusion of ivermectin in malaria control programs.

“This research has the potential to shape the future of malaria prevention, particularly in endemic areas where existing tools are failing,” concludes Regina Rabinovich, BOHEMIA PI and Director of ISGlobal’s Malaria Elimination Initiative. “With its novel mechanism of action and proven safety profile, ivermectin could offer a new approach using a well-known, safe drug that can add to the effect of other mosquito control tools available today.”